T1	intervention 35 56	endometrial resection
T3	condition 68 96	recurrent endometrial polyps
T4	eligibility 100 144	women with breast cancer receiving tamoxifen
T6	condition 204 257	recurrence of tamoxifen-associated endometrial polyps
T7	No-of-participants 404 410	Twenty
T8	average-age 440 449	43-61 yrs
T9	ethinicity 318 326	Canadian
T10	intervention-participants 613 615	10
T11	control-participants 639 641	10
T13	duration 710 719	18 months
T14	outcome-Measure 880 912	recurrence of endometrial polyps
T15	outcome-Measure 914 944	occurrence of uterine bleeding
T16	intervention-value 1012 1015	one
T17	outcome 1031 1048	endometrial polyp
T18	intervention-value 1089 1094	Seven
T19	outcome 1110 1121	amenorrheic
T20	intervention-value 1127 1132	three
T21	outcome 1145 1153	spotting
T22	control-value 1204 1207	six
T2	control 626 637	not undergo
T5	outcome 1218 1278	recurrent endometrial polyps requiring hysteroscopic removal
